Prognostic evaluation of cardiac biomarker elevation after percutaneous and surgical revascularization in the absence of manifested myocardial infarction: a comparative analysis of biomarkers and cardiac magnetic resonance

Zerbini Foundation [Fundação Zerbini] (Brazil)0 个研究点目标入组 155 人开始时间: 2012年5月8日最近更新: 2024年7月29日

适应症

试验速览

2016 Results article in http://www.ncbi.nlm.nih.gov/pubmed/26912303 results 2017 Results article in http://www.ncbi.nlm.nih.gov/pubmed/29201152 results 2017 Results article in http://www.ncbi.nlm.nih.gov/pubmed/29284532 results 2020 Results article in https://pubmed.ncbi.nlm.nih.gov/33280019/ results (added 07/12/2020) 2024 Other publications in https://pubmed.ncbi.nlm.nih.gov/38982515/ subanalysis in patients with stable coronary artery disease with and without type 2 diabetes (added 16/07/2024)

•1. Recent myocardial infarction (=6 months)
•2. Signs of manifest or suspected infections
•3. Rheumatologic disease activity
•4. Chronic renal failure (creatinine level >2.0mg/dL)
•5. Recent (= 6 months) pulmonary embolism or venous thromboembolism
•6. Does not sign the consent form
•7. Contraindication for the use of glycoprotein IIb/IIIa inhibitors
•8. Cardiac magnetic resonance (CMR) examination, for example, a person with a pacemaker or severe claustrophobia

发起方

Zerbini Foundation [Fundação Zerbini] (Brazil)